China Pharma (NYSEAMERICAN:CPHI) Share Price Passes Above 200-Day Moving Average of $0.00

Shares of China Pharma Holdings, Inc. (NYSEAMERICAN:CPHIGet Rating) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.26. China Pharma shares last traded at $0.25, with a volume of 217,355 shares.

The company has a market capitalization of $11.83 million, a P/E ratio of -2.72 and a beta of 0.25.

China Pharma (NYSEAMERICAN:CPHIGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.02) EPS for the quarter. The company had revenue of $1.60 million during the quarter. China Pharma had a negative return on equity of 50.83% and a negative net margin of 37.46%.

A hedge fund recently raised its stake in China Pharma stock. Renaissance Technologies LLC raised its position in shares of China Pharma Holdings, Inc. (NYSEAMERICAN:CPHIGet Rating) by 43.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 700,649 shares of the company’s stock after purchasing an additional 213,170 shares during the quarter. Renaissance Technologies LLC owned 1.61% of China Pharma worth $391,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.64% of the company’s stock.

About China Pharma (NYSEAMERICAN:CPHI)

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.

Further Reading

Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with's FREE daily email newsletter.